Rossari Biotech Limited announced a significant milestone in its capacity expansion plans as its material subsidiary Unitop Chemicals Private Limited successfully commissioned additional ethoxylation capacity at its Dahej facility. The development marks the completion of the second phase of a major expansion project that strengthens the company's manufacturing capabilities in the specialty chemicals sector.

Capacity Expansion Details

Unitop Chemicals has commissioned the remaining 15,000 MTPA ethoxylation capacity out of the total planned 30,000 MTPA expansion at its facility in Dahej, effective from March 31, 2026. This represents the completion of the capacity addition project that was previously announced through multiple regulatory filings.

Enhanced Production Capabilities

With this latest commissioning, Unitop's total installed ethoxylation capacity now stands at 66,000 MTPA. The expansion significantly enhances the subsidiary's production capabilities and positions it to better serve growing market demand for specialty chemical products.

Regulatory Compliance

The announcement was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company had previously provided updates on this capacity expansion project through intimations dated October 19, 2023, October 17, 2024, and September 26, 2025, demonstrating consistent progress tracking and regulatory compliance.

Strategic Significance

The successful commissioning of this additional capacity represents a key milestone for Rossari Biotech's subsidiary operations. Unitop Chemicals, being a material subsidiary of the company, plays a crucial role in the overall business strategy. The expanded ethoxylation capacity at the Dahej facility enhances the company's ability to meet increasing demand in the specialty chemicals market and supports its growth objectives in this segment.

Rossari Biotech Limited has announced a corporate name change for its wholly owned subsidiary operating in Dubai's financial free zone. The company informed stock exchanges about this regulatory compliance update on March 24, 2026.

Subsidiary Name Change Details

The company's wholly owned subsidiary has undergone a name modification as per local regulatory requirements:

Regulatory Compliance

The name change represents compliance with mandatory guidelines from the Dubai Multi Commodities Centre Authority. The company specifically noted that the modification pertains only to the suffix of the subsidiary's name, indicating a structural requirement rather than a fundamental business change.

Corporate Communication

Rossari Biotech fulfilled its disclosure obligations under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company communicated this development to both major Indian stock exchanges where its shares are listed.

The information has been made available on the company's official website at www.rossari.com for stakeholder reference. This transparency measure ensures all concerned parties have access to the updated subsidiary information.

Administrative Details

The formal communication was signed by Parul Gupta, Head - Company Secretary & Legal, with membership number A38895. The digital signature was authenticated on March 24, 2026, confirming the official nature of this corporate announcement.